Ligelizumab Completed Phase 1 Trials for Allergies Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science1
clinicaltrials.gov IdentifierTitleDrugs
NCT01596712Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects